Triple positive breast cancer (BC; estrogen receptor/progesterone receptor [ER/PR]/HER-2 positive) constitutes only about 10% of all BCs.1 Metachronous contralateral BC (MCBC) is defined as contralateral BC diagnosed more than 1 year after previous BC diagnosis. Here, ERBB2 is linked to breast cancer.